Kornimate/medical-research-clean huggingface dataset:
genetic determinants of warfarin anticoagulation effect

Conditions: Venous Thrombosis; Pulmonary Embolism; Atrial Fibrillation

Summary: the response to warfarin varies greatly among individuals. some of this variability can be ascribed to genetic polymorphisms in the gene encoding for cyp2c9, the enzyme mediating the metabolism of s warfarin. in addition genetic polymorphism in other genes (i.e. vkorc1, factor vii) have been shown to account for some of the variability in the response to warfarin irrespective of cyp2c9.the present study has several segments: 1. evaluation of the relationship between genetic polymorphisms in the genes encoding for cyp2c9, vkorc1 and factor vii and warfarin maintenance dose at steady state. this study is a confirmation of previous data in our own population. 2. evaluation of relationship between genetic polymorphisms in the genes encoding for cyp2c9, vkorc1 and factor vii and warfarin loading dose during the induction period. 3. testing the hypothesis that warfarin loading based on the individual's combined cyp2c9, vkorc1 and factor vii genotype may be more efficient and associated with reduced adverse drug effects.


Eligibility criteria:
inclusion criteria: * patients in whom warfarin is about to be initiated * desired therapeutic range \>2 and \<3 exclusion criteria: * refusal to participate in the study
epstein-barr virus status in diffuse large b cell lymphoma

Conditions: Diffuse Large B-cell Lymphoma

Summary: the investigators analyzed clinical outcome in dlbcl patients according to age group to define the impact of ebv status on the clinical outcome.

epstein-barr virus (ebv) positive diffuse large b-cell lymphoma (dlbcl) has been recognized as a new provisional entity in the 2008 world health organization (who) classification of tumors of hematopoietic and lymphoid tissue. this lymphoma is defined as ebv+ clonal b-cell proliferation in immunocompetent adults older than 50 years. to denote patient age in definition of this disease, age cutoff was defined as older than 50 years. however, this cutoff is clearly arbitrary without any scientific background. the knowledge on ebv+dlbcl in young adult is very scanty. this ebv+dlbcl in young adult can be the same disease entity or it can be a distinct disease form ebv+dlbcl of elderly.

Eligibility criteria:
inclusion criteria: * pathologically confirmed de novo dlbcl, according to the world health organization (who) classification: * registered in samsung medical center (smc) lymphoma cohort study i/ii (clinicaltrials.gov identifier: nct00822731, nct01877109) or identified from asan medical center (amc) medical database: * adequate amount and quality of paraffin-embedded biopsy specimen or unstained slides for ebv-encoded rna (eber) in situ hybridization. exclusion criteria: * patients with unknown ebv status, primary central nervous system (cns) lymphoma, post-transplant lymphoproliferative disorders (ptlds), and hiv-positive dlbcl were excluded in the study.

Keywords: diffuse large b-cell lymphoma ebstein-barr virus
virtual reality goggle utilization for venipuncture distraction

Conditions: Pain, Procedural

Summary: this is a randomized non-blinded trial evaluating the effect of virtual reality goggles on perceived pain and anxiety scores during venipuncture on hospitalized children ages 5-21. we will randomized patients to either standard of care (including lidocaine 2.5%/prilocaine 2.5% cream as a topical anesthetic 60-240 minutes prior to venipuncture) or standard of care plus virtual reality goggles.

study personnel will identify patients on cham 6 and cham 8 scheduled for lab draw prior to child life rounds and subsequently ask the health care providers if there are any patients that are not developmentally or physically appropriate to use the vr equipment. they will then screen and consent the patients approximately 1 hour prior to the child life rounds (see appendix a \& b). patients aged 12-17 years old who are able to read the form will be asked to fill out an assent form (see appendix c) and patients aged 5-12 years old and those unable to read the form will be read the assent form to ensure verbal assent. those patients who consent to the study will be randomized to a vr arm and non vr arm using computer generated randomization. lidocaine 2.5%/prilocaine 2.5% cream will be placed on all patients that have consented to the study by the patient's nurse if they don't already have it applied. after consent and assurance of topical anesthetic application, a brief demographic questionnaire (see appendix d) will also be completed. for efficiency and feasibility, two study personnel will screen and consent families, assist with vr set up and removal, and conduct post procedure assessment.

Eligibility criteria:
inclusion criteria: patients aged 5-21 years old admitted to the 6th floor of the inpatient unit who are scheduled for a venipuncture during morning phlebotomy rounds exclusion criteria: patients developmentally or physically not appropriate to use the vr equipment as determined by their parent, guardian or healthcare provider, if there is discomfort related to wearing the goggles (for example: recent neurosurgery, migraines, hardware on head), patient have photosensitive seizures or infectious concern such as scabies, lice, covid-19 that can't reliably be disinfected. patient (\>18) or parent or guardian (for patient \< 18) that does not speak english, spanish or arabic will be excluded. if patient refuses lidocaine 2.5%/prilocaine 2.5% cream use they will also be excluded from the study. -

Keywords: virtual reality
assessment of the feasibility of using a smartphone application for the prevention and screening of burnout (burnout advice)

Conditions: Burnout, Professional

Summary: burnout syndrome has been recognized as a mental illness since 2020. all workers can be affected. the consequences are multiple and often serious, ranging from stoppage of work to depression or even suicide. according to a 2019 survey by malakoff, 56% of employees are in "professional or personal fragility", but the statistics are incomplete. in the medical community, the burnout rate is doubled compared to the general population. the diagnosis of pre-burnout can precede a burnout by several months, an early treatment can then reduce complications and improve the quality of life at work. on a study model on health data already carried out as part of a cancer detection application in smokers which involved 7000 users and which showed the ability to of such an application to detect curable symptomatic cancers from questionnaires (24% with application against 9% without application), we will carry out a descriptive evaluation of the use of an application to detect pre-burnout, burnout and depressive syndrome in a worker population. in the event of a risk alert of pre-burnout, burnout or depressive syndrome, the application will display a message to the user suggesting that he consult his general practitioner or put him in contact with a doctor through a teleconsultation via a dedicated platform. this first study will assess the feasibility and acceptability of an early detection approach among professionals of a state of "fragility" (pre-burnout, burnout or depressive syndrome). subsequently, a larger study will evaluate the effectiveness of this application for the early detection of burnout among professionals, its management and the reduction of costs for the healthcare system and society.


Eligibility criteria:
inclusion criteria: * person aged 18 to 64 * exercising a professional activity * user informed of the use of this data and not objecting to it exclusion criteria: * professionals on sick leave
the correlation between mage-a3, prame polymorphism and expression levels of mage-a3 and prame in nsclc patients

Conditions: Carcinoma, Non-Small-Cell Lung

Summary: considering the low expression rate of melanoma-associated antigen 3 (mage-a3) in asian especially southeast asian, it would be great interests to investigate the potential polymorphism of mage-a3 in non-small-cell lung cancer (nsclc) patients in taiwan. meanwhile, it is also interesting to study the expression of preferentially expressed antigen in melanoma(prame) and epidermal growth factor receptor (egfr) mutation status as well as to find out significant factors which may affect their expression such as smoking status, histological types, tumour size and stages in taiwan.

considering the low expression rate of mage-a3 in asian especially southeast asian, it would be great interests to investigate the potential polymorphism of mage-a3 in nsclc patients in taiwan. meanwhile, it is also interesting to study the expression of prame and egfr mutation status as well as to find out significant factors which may affect their expression such as smoking status, histological types, tumour size and stages in taiwan

Eligibility criteria:
inclusion criteria: - tissues samples up to 200 cases of nscls patients with informed consent, consisting of about 100 cases of adenocarcinoma (ac) and 100 cases of squamous cell carcinoma (scc), with stage of ib, iia, iib and iiia exclusion criteria: - no
effect and safety of propofol fumarate for mother-to-child blocking of hepatitis b

Conditions: Chronic Hepatitis B Infection; High Viral Load

Summary: this study is a prospective study. the subject will select 440 cases of pregnant women with high hepatitis b virus load, and one group will take maternal and child blockade treatment with propofol fumarate. one group will take tenofovir disoproxil fumarate. broken treatment, compare the failure rate of maternal and child blockade and the incidence of maternal and child adverse events in the two groups, and explore the efficacy and safety of propofol flavuril for the treatment of hepatitis b mother-infant block.

this study was a prospective cohort study. because propofolofofovir is not covered by medical insurance and is more expensive, and there are factors such as renal function damage and the risk factors that can not use tenofovir, it is difficult to conduct randomized controlled cases. the subject will select 440 cases of pregnant women with high hepatitis b virus load. after signing the informed consent form, according to the patient's wishes, one group will take the mother-infant blockade of propofol fumarate, and one group will take fumaric acid. in the case of maternal and child blockade of benifovir, the incidence of maternal and child block failure and the incidence of maternal and child adverse events were compared between the two groups, and propofol fumarate was used for maternal and child blockade of hepatitis b. the effectiveness and safety of the treatment.

Eligibility criteria:
inclusion criteria: * no nucleoside analog antiviral drugs have been used in the past. * hbsag and hbeag double positive, hbv dna\>106 iu/ml. * fully inform the risk to voluntarily join the study and sign the informed consent form. exclusion criteria: * combine other viral infections: such as hcv, hiv, cmv, etc.; * amniocentesis during pregnancy; * liver cirrhosis and liver cancer; * other autoimmune diseases and liver diseases; * fetal ultrasound screening in early and middle pregnancy found deformity.

Keywords: chronic hepatitis b pregnant woman high viral load tenofovir fumarate
use of tpco2 (transcutaneous co2 measurement) as paco2 predictor during niv in case of acute hypercapnic respiratory failure

Conditions: Hypercapnic Respiratory Failure

Summary: in patients suffering from hypercapnic respiratory failure and treated by non invasive ventilation (niv), the interest of using transcutaneous co2 measurement to evaluate paco2 and paco2 variation over time is unknown and will be evaluated in this study. measurements will be done during one-hour niv treatments.


Eligibility criteria:
inclusion criteria: * icu patient equipped with an arterial line * niv treatment prescribed by the clinician in charge * hypercapnia defined by paco2\> 42mmhg exclusion criteria: * severe hemodynamic instability * severe psychiatric disorders * denied consent * age \< 18 years

Keywords: acute respiratory failure hypercapnia non invasive ventilation transcutaneous co2 measurement
two different blocks for postoperative analgesia in patients undergoing unilateral total knee arthroplasty

Conditions: Knee Replacement, Total; Pain, Postoperative; Anesthesia, Regional

Summary: the frequency of femoral nerve block and adductor canal block for analgesia after tka(total knee arthroplasty) increases with the use of ultrasonography in regional anesthesia. in this study, we aimed to compare the effects of femoral nerve block and adductor canal block on postoperative analgesia in patients undergoing unilateral knee arthroplasty.


Eligibility criteria:
inclusion criteria: * asa(american society of anesthesiologists) classification i-ii * age: \<55 years * unilateral total knee arthroplasty exclusion criteria: * does not approve the study * pregnant * emergency * asa iii-iv * history of local anesthetic allergy * infection in the block area * coagulation disorder * morbid obesity (body mass index\> 40 kg / m²) * severe organ failure * previous neurological deficit * psychiatric disease * history of chronic pain

Keywords: femoral nerve block, adductor canal block, total knee arthroplasty
adult intracranial ependymoma

Conditions: Intracranial Ependymoma

Summary: adult intracranial ependymoma is a relatively rare brain tumour entity, accounting for 2-5% of all intracranial neoplasms. the pertinent prognostic factors as well as the pattern of recurrence remain to be elucidated. according to several recent reports, the prognostic value of karnofski performance status, tumour location, the extent of surgical removal, histological grade and even postoperative radiotherapy remain controversial. as a consequence, optimal therapeutic management of adult intracranial ependymomas remains an ongoing debate. for this reason, a retrospective study conducted by the french society of neurosurgery (sfnc), neuropathology (sfnp) and the association of the neuro-oncologists of french expression (anocef) was undertaken and allowed to collect 258 cases coming from 25 centers, initially diagnosed as intracranial ependymomas between 1990 and 2004. clinical and follow-up data of these patients are known and the paraffin embedded samples as well as the frozen tissues available have been centralized. central pathological review of these 258 cases was conducted by two senior neuropathologists and confirmed the diagnosis of ependymoma in 152 cases, thus constituting the most important series of the literature. few molecular studies were carried out on ependymomas. the investigators have the opportunity, based on this important series, to determine the clinicopathological criteria and the molecular markers who will allow a better characterization of the diagnosis and the prognosis of these tumors.


Eligibility criteria:
inclusion criteria: * diagnosis later(posterior) than january, 1990 * diagnosis previous to june, 2004 * available postoperative mri at the not dead patients during operating * diagnosis of eica held(retained) after centralized second reading * absence of histories of radiotherapy and\\or chemotherapy for a brain damage exclusion criteria: * diagnosis previous to january, 1990 * diagnosis later(posterior) than june, 2004 · * diagnosis of eica not held(retained) after centralized second reading * histories of radiotherapy and\\or chemotherapy for a brain damage

Keywords: adult intracranial ependymoma
a study of participants with advanced non-small cell lung cancer treated with nivolumab in france after at least one prior chemotherapy-based treatment by lung initiative on sequence therapy

Conditions: Lung Cancer

Summary: the purpose of this trial is to describe the following, for each cohort, in real world conditions in france: * the characteristics and treatment sequence of patients treated with nivolumab * the effectiveness of nivolumab treatment * the safety profile of nivolumab * treatment patterns (e.g. duration of treatment, subsequent treatments) of nivolumab * the patient-reported outcomes (pro) in patients treated with nivolumab, at baseline and during follow up using the euroqol-5d-3l


Eligibility criteria:
for more information regarding bristol-myers squibb clinical trial participation, please visit www.bmsstudyconnect.com inclusion criteria: * pathologically confirmed diagnosis of advanced nsclc * whose physician has already decided to initiate a treatment with nivolumab for the treatment of advanced nsclc according to the european label * previously treated with at least one prior chemotherapy- containing regimen exclusion criteria: * participants taking part in an interventional study for lung cancer treatment for which nivolumab is one of the investigational drugs * participants with a diagnosis of another primary cancer within the past five years * participants receiving io within 12 weeks prior to nivolumab first infusion in the context of the present study other protocol-defined inclusion/exclusion criteria apply

Keywords: non small cell lung cancer
observatory of patients with myeloproliferative neoplasm treated with anti-inflammatory immunotherapy

Conditions: Myeloproliferative Neoplasm; Inflammatory Disease

Summary: the study will collect cases of mpn patients who also benefit from an anti-inflammatory immunotherapy for another disease. efficacy and tolerability of the drug will be assessed in this population.


Eligibility criteria:
inclusion criteria: * myeloproliferative neoplasm diagnosis * receiving or having received an immunotherapy targeting il-1, il-6, il-17, il-23 or tnf exclusion criteria: * unable to consent
optimal coronary sinus lead implantation using intracardiac impedography and magnetic resonance imaging

Conditions: Heart Failure, Systolic; Left Bundle Branch Block

Summary: despite the dramatic effect of cardiac resynchronization therapy (crt) on survival and morbidity in people with congestive heart failure, 50-70% of eligible patients do not respond to this intervention. there is retrospective evidence that placement of the left ventricular (lv) lead at the region of latest mechanical delay markedly improves response to crt. however, there is no feasible way to gauge dyssynchrony at lv lead sites during crt implantation. impedance recordings from pacing lead tips allow for real-time assessment of mechanical motion and may represent a useful intraoperative tool to guide optimum placement of the lv lead during crt implantation. this pilot trial will assess the use of intraoperative impedograms in humans to measure regional dyssynchrony at potential lv lead locations during crt implantation.

this is a clinical trial using intracardiac impedance signals (impedograms) to assess regional dyssynchrony at various sites of left ventricular (lv) lead placement in humans undergoing crt device implantation. this study will test the following hypotheses during the funding period: 1. lv lead impedograms as an implant tool to place leads at sites of latest mechanical delay are feasible and correlate with other means of assessing dyssynchrony. 2. lv lead impedograms vary significantly depending on lv lead location. 3. there are several characteristics of lv lead impedograms that correlate with mechanical phenomena of the heart.

Eligibility criteria:
inclusion criteria: * patients with nyha class iii or iv heart failure * lvef ≤ 30% * qrs duration ≥ 120 ms exclusion criteria: * not a candidate for crt implantation

Keywords: heart failure cardiac resynchronization therapy regional left ventricular dyssynchrony crt
evaluating the physiological strain induced by a bc membrane protective garment under exercise-heat stress compared to a protective coverall

Conditions: Physiological Stress

Summary: israel ministry of defense is examining a new bc membrane protective garment of blauer company constructed with gore chempak fabric for the border guard of the police forces. the goal of this research is to perform a comparative experiment in order to evaluate the physiological strain induced by the new protective garment under exercise-heat stress conditions, compared to protective garment in current use.

in order to physiologically evaluate a new bc membrane protective garment for the israeli police use under exercise-heat stress conditions, 12 healthy volunteers from the border guard will participate in this study. the subjects will undergo 4 experiment days: recruitment day, one day of acclimatization to heat, and 2 days of performing experiment protocol, each day dressed with different protective garment (protective garment in current use + nbc mask, new bc membrane protective garment + nbc mask). core (rectal) and skin temperature and heart rate will be monitored continuously, liquid balance will be recorded.the physiological heat strain will be assessed and compared between the different protective garments.

Eligibility criteria:
inclusion criteria: * aged 18-40 years. * healthy civilian volunteers. * without known medical illness or medication use. exclusion criteria: * the existence or suspicion of existing cardiac or respiratory disease. * hypertension. * diabetes. * psychiatric condition. * any muscles or skeleton condition. * any hormonal disease or any other chronic illness that may inhibit participation in the experiment. * infectious disease 3 days prior to the experiment.
lianhua qingwen for the rehabilitation of patient with coronavirus infection

Conditions: Coronavirus; Traditional Chinese Medicine

Summary: the patients with coronavirus infection usually have fever, respiratory symptoms, headache, toothache, muscle soreness, physical decline, and so on, while others are asymptomatic patients. it is urgent to find drugs to improve the long-term rehabilitation of symptomatic patients with coronavirus infection and decrease the duration of viral shedding in both symptomatic and asymptomatic patients. this study aims to investigate the efficacy and safety of lianhua qingwen capsules in patients with coronavirus infection. the duration of viral shedding and symptoms before discharge, as well as the negative conversion ratio and disappearance ratio of main symptoms after 7-day treatment, will be evaluated. 6-month follow-up will be performed to evaluate the effect of lianhua qingwen on all infection events and the long-term rehabilitation of the symptoms induced by coronavirus infection.


Eligibility criteria:
inclusion criteria: * confirmed sars-cov-2 infection by virus testing; * ≥18 years of age; * informed consent provided. exclusion criteria: * overt bacterial infection in the respiratory tract resulting from common pathologies, including primary immunodeficiency disease, acquired immunodeficiency syndrome, congenital respiratory malformation, congenital heart disease, gastroesophageal reflux disease, and abnormal lung development; * asthma treated daily, chronic airway disease, respiratory bacterial infections (e.g., purulent tonsillitis), acute tracheobronchitis, sinusitis, otitis media, and further respiratory tract pathologies potentially affecting the trial's data analysis; * common pulmonary diseases (e.g., severe pulmonary interstitial lesions and bronchiectasis) confirmed by chest ct; * severe pneumonia requiring ventilator use; * previous or present diseases potentially affecting trial participation or influencing study outcome, based on the investigator's judgment; * pregnancy or lactation in women; * participation in a clinical study in the past 3 months; * history of allergy to ≥2 drugs or foods or known allergy to the drug's constituents.